Physician profile
Danielle Gabriel
NPI 1023776614
$1,770.66
in general payments reported to CMS, 2019-2025
15 companies · $817 in 2025
The $817 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $416 · 2023: $264 · 2024: $275 · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,355.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $426.02 | 2022-2025 | Linq II, Micra, Aurora Ev-Icd Mri Surescan |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $357.61 | 2022-2025 | Lifevest |
| Heartflow, INC. | $194.29 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $177.61 | 2023-2025 | Camzyos, Eliquis |
| Abiomed | $130.65 | 2022-2023 | Impella |
| Actelion Pharmaceuticals US, INC. | $122.17 | 2024 | Opsumit, Uptravi |
| Astellas Pharma US INC | $103.20 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $73.89 | 2022-2023 | Farxiga |
| Kestra Medical Technology Services, INC. | $48.42 | 2022 | |
| Pfizer INC. | $37.96 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.90 | 2022 | |
| Scpharmaceuticals INC. | $20.84 | 2025 | |
| Novo Nordisk INC | $16.90 | 2023 | |
| Amgen INC. | $15.05 | 2023 | Repatha |
| Boston Scientific Corporation | $14.15 | 2023 | Watchman Flx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Gabriel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.